NextCure has inked a $745 million deal to secure ex-Greater China rights to Simcere Zaiming’s phase 1-stage antibody-drug conjugate (ADC) SIM0505, targeting CDH6. The ADC combines a targeted antibody with a topoisomerase 1 inhibitor payload designed for broad anti-tumor activity with improved safety. NextCure plans to initiate U.S. clinical trials in Q3 2025. The agreement includes access to Simcere’s linker and payload technologies for NextCure’s proprietary ADC development. This move represents a strategic pivot for NextCure towards ADCs after discontinuing other candidates.